摘要
目的:探讨多种肿瘤耐药因子在肺癌的表达及其临床意义。方法:应用免疫组织化学法检测66例肺癌标本各种肿瘤耐药因子的表达水平。结果:1)突变型P53蛋白、P-糖蛋白(Pgp)、多药耐药相关蛋白(MRP1)、肺耐药相关蛋白(LRP)、谷胱甘肽-S-转移酶-π(GST-π)、拓扑异构酶Ⅱ1(TOPOⅡ1)的表达率分别为74.24%、45.45%、51.52%、81.82%、81.82%、83.33%。2)不同耐药因子在不同肺癌的表达具有不同的特点,特别是在表达强度方面NSCLC(非小细胞肺癌)与SCLC(小细胞肺癌)存在显著差异性(P<0.05);且表达强阳性与不同的病理类型、TNM分期、分化程度、淋巴结转移及预后方面均存在显著差异性(P<0.05)。3)各耐药因子之间的相关性分析表明:P53蛋白、Pgp、MRP、GST-π的表达之间存在着显著相关性,而LRP、TOPOⅡ1可能是相对独立的耐药因素。结论:肺癌组织肿瘤耐药因子的表达可能在一定程度上提示肺癌的化疗效果和预后。
Objective： To investigate the expression and clinical significance of various drug resistance factors in lung cancer. Methods： Immunohistochemistry was used to determine the expression level of various tumor drug resistance factors in 66 samples of lung cancer. Results： a） The expression of P53, Pgp, MRP1, LRP, GST-π and TOPOⅡɑ was 74.24%, 45.45%, 51.52%, 81.82%, 81.82% and 83.33%, respectively. b） Different drug resistance factors had different expression characteristics in various lung cancers, specifically, there was a significant difference in the expression strength between the non-small cell lung cancer （NSCLC） and small-cell lung cancer （SCLC） （P〈0.05）. In addition, there was a significant difference between the strong positive expression and the different histological types, TNM stages, differentiation, lymph node metastasis and prognosis（P〈0.05）. c） The correlation analysis among the drug resistance factors showed that there was a significant correlation among P53, Pgp, MRP1 and GST-π, but the LRP and TOPOⅡɑ might be relatively independent drug resistance factors. Conclusion： The combination of expression of various drug resistance factors may predict the effect of chemotherapy and prognosis of lung cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2007年第4期215-218,共4页
Chinese Journal of Clinical Oncology
基金
广州市重点攻关项目资助(编号:20012036012)
关键词
肺肿瘤
免疫组织化学
多药耐药
Lung tumor
Immunohistochemistry
Multidrug resistance
